Carcinoid Syndrome Management Market Research Report- Global Forecast To 2030

Carcinoid Syndrome Management Market Research Report Information, by organs affected (Small Intestine, Lungs, Rectum, Appendix, Colon, Stomach, Pancreas, Liver and others) by Treatment (Chemotherapy, Biological therapy, and Hepatic Artery Embolization Agents), by End users (Hospital, Clinics, Cancer institute and treatment centers) Forecast to 2030

ID: MRFR/MED/2100-HCR | 85 Pages | Author: Rahul Gotadki | May 2023         

Table of Contents

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED

5.1 SMALL INTESTINE

5.2 RECTUM

5.3 LUNGS

5.4 APPENDIX

5.5 COLON

5.6 STOMACH

5.7 PANCREAS

5.8 LIVER

5.9 OTHERS

6. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE

6.1 CHEMOTHERAPY

6.3 BIOLOGICAL THERAPY

6.4 HEPATIC ARTERY EMBOLIZATION AGENT

7. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY END USERS

7.1 HOSPITALS

7.2 CLINICS

7.3 CENCER INSTITUTIONS AND TREATMENT CENTERS

7.4 OTHERS

8. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION

8.1 NORTH AMERICA

8.1.1 INTRODUCTION

8.2 EUROPE

82.1 INTRODUCTION

8.3 ASIA-PACIFIC

8.3.1 INTRODUCTION

8.4 MIDDLE EAST & AFRICA

8.4.1 INTRODUCTION

9. COMPETITIVE LANDSCAPE

9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

9..1.1 STRATEGIC PARTNERSHIP

10..1.2 MERGER & ACQUISITION

10 COMPANY PROFILE

10.1 BTG INTERNATIONAL LTD.

10.1.1 OVERVIEW

10.1.2 PRODUCT OVERVIEW

10.1.3 FINANCIALS

10.1.4 KEY DEVELOPMENTS

10.2 IPSEN BIOPHARMACEUTICALS, INC.,

10.2.1 OVERVIEW

10.2.2 PRODUCT OVERVIEW

10.2.3 FINANCIALS

10.2.4 KEY DEVELOPMENTS

10.3 NOVARTIS INTERNATIONAL AG (SANDOZ)

10.3.1 OVERVIEW

10.3.2 PRODUCT OVERVIEW

10.3.3 FINANCIALS

10.3.4 STRATEGY

10.3.5 KEY DEVELOPMENT

10.4 PHARMASCIENCE INC.,

10.4.1 OVERVIEW

10.4.2 PRODUCT OVERVIEW

10.4.3 FINANCIALS

10.4.4 KEY DEVELOPMENTS

10.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.

10.5.1 OVERVIEW

10.5.2 PRODUCT OVERVIEW

10.5.3 FINANCIALS

10.5.4 KEY DEVELOPMENTS

10.6 OTHERS

List of Tables

TABLE 1 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED, 2020-2027 (USD MILLION)

TABLE 2 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKETBY END USERS 2020-2027 (USD MILLION)

TABLE 4 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED

FIGURE 4 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE

FIGURE 5 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY END USERS

FIGURE 6 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION

FIGURE 7 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid